ISIN | LU1540962211 |
---|---|
Valor Number | 35004490 |
Bloomberg Global ID | |
Fund Name | HBM Global Biotechnology Fund P EUR Cap |
Fund Provider |
HBM Partners AG
Zug, Schweiz Phone: +41 43 888 71 71 E-Mail: investorrelations@hbmpartners.com Web: www.hbmpartners.com |
Fund Provider | HBM Partners AG |
Representative in Switzerland |
FundPartner Solutions (Suisse) SA Genève 75 |
Distributor(s) | FundPartner Solutions (Suisse) S.A. |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The investment objective of the Sub-Fund is to achieve long-term capital growth. The goal is to generate a value trend that exceeds the performance of the NASDAQ Biotechnology Index (the “Benchmark”). No guarantee can be given that the investment objective will be achieved. |
Peculiarities |
Current Price * | 124.89 EUR | 04.07.2024 |
---|---|---|
Previous Price * | 124.50 EUR | 03.07.2024 |
52 Week High * | 127.93 EUR | 27.02.2024 |
52 Week Low * | 94.87 EUR | 27.10.2023 |
NAV * | 124.89 EUR | 04.07.2024 |
Issue Price * | 124.89 EUR | 04.07.2024 |
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 23,677,953 | |
Unit/Share Assets *** | 172,730 | |
Trading Information SIX |
YTD Performance | +2.75% |
29.12.2023 - 04.07.2024
29.12.2023 04.07.2024 |
---|---|---|
YTD Performance (in CHF) | +7.67% |
29.12.2023 - 04.07.2024
29.12.2023 04.07.2024 |
1 month | +4.95% |
04.06.2024 - 04.07.2024
04.06.2024 04.07.2024 |
3 months | +3.04% |
04.04.2024 - 04.07.2024
04.04.2024 04.07.2024 |
6 months | +2.55% |
04.01.2024 - 04.07.2024
04.01.2024 04.07.2024 |
1 year | +13.70% |
04.07.2023 - 04.07.2024
04.07.2023 04.07.2024 |
2 years | +17.26% |
06.07.2022 - 04.07.2024
06.07.2022 04.07.2024 |
3 years | -12.22% |
07.07.2021 - 04.07.2024
07.07.2021 04.07.2024 |
5 years | +18.18% |
10.07.2019 - 04.07.2024
10.07.2019 04.07.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Zealand Pharma A/S | 5.90% | |
---|---|---|
Vertex Pharmaceuticals Inc | 5.84% | |
Regeneron Pharmaceuticals Inc | 5.76% | |
Amgen Inc | 5.67% | |
Blueprint Medicines Corp | 4.73% | |
argenx SE | 4.73% | |
Gilead Sciences Inc | 4.38% | |
Neurocrine Biosciences Inc | 4.13% | |
Biohaven Ltd | 3.27% | |
Ascendis Pharma A/S ADR | 3.02% | |
Last data update | 31.03.2024 |
TER | 0.0014% |
---|---|
TER date | 31.01.2018 |
Performance Fee *** | 15.00% |
PTR | |
Max. Management Fee *** | 1.10% |
Ongoing Charges *** | 1.76% |
SRRI ***
|
|
SRRI date *** | 30.06.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |